close

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology for the development of generic versions of complex drug products, as well as for the discovery and development of novel drugs. Its product candidates include M-Enoxaparin, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; and M118, an anticoagulant. The company also involves in developing generic or biosimilar glycoprotein products. Momenta Pharmaceuticals has collaborations with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals was founded in 2001 and is based in Cambridge, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	15.54
Volume	751584
Volume Avg	953438
52 Week High	21.00
52 Week Low	10.15
PE	4.39
PE (group average)	39
EPS Year	3.55
EPS change Q/Q	45.57%
EPS change Q/Q Yr ago	-1000%
EPS change Q/Q next Q est	-1000%
EPS change Y/Y	1000%
REV change Q/Q	34.13%
REV change Q/Q Yr ago	2013.51%
EPS next Q est	-0.17
EPS next Y est	-0.88
Divident Annual	0.00
Dividend Yield	0%